This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2021 Aug 17;42(31):3025-3026.

doi: 10.1093/eurheartj/ehab233.

The EVAPORATE trial provides important mechanistic data on plaque characteristics that have relevance to the REDUCE-IT results and clinical use of icosapent ethyl

Matthew Budoff¹, Suvasini Lakshmanan¹, Deepak L Bhatt²

Affiliations

Affiliations

¹ Department of Medicine, Lundquist Institute at Harbor-UCLA Medical Center, 1124 W Carson Street, Torrance, CA 90502, USA.
² Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, 75 Francis Street Boston, MA 02115, USA.

PMID: 33970207
DOI: 10.1093/eurheartj/ehab233

Comment

The EVAPORATE trial provides important mechanistic data on plaque characteristics that have relevance to the REDUCE-IT results and clinical use of icosapent ethyl

Matthew Budoff et al. Eur Heart J. 2021.

. 2021 Aug 17;42(31):3025-3026.

doi: 10.1093/eurheartj/ehab233.

Authors

Matthew Budoff¹, Suvasini Lakshmanan¹, Deepak L Bhatt²

Affiliations

¹ Department of Medicine, Lundquist Institute at Harbor-UCLA Medical Center, 1124 W Carson Street, Torrance, CA 90502, USA.
² Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, 75 Francis Street Boston, MA 02115, USA.

PMID: 33970207
DOI: 10.1093/eurheartj/ehab233

Erratum in

Corrigendum to: The EVAPORATE trial provides important mechanistic data on plaque characteristics that have relevance to the REDUCE-IT results and clinical use of icosapent ethyl.
[No authors listed] [No authors listed] Eur Heart J. 2021 Oct 7;42(38):3991. doi: 10.1093/eurheartj/ehab351. Eur Heart J. 2021. PMID: 34151350 No abstract available.

No abstract available

PubMed Disclaimer

Comment on

Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.
Budoff MJ, Bhatt DL, Kinninger A, Lakshmanan S, Muhlestein JB, Le VT, May HT, Shaikh K, Shekar C, Roy SK, Tayek J, Nelson JR. Budoff MJ, et al. Eur Heart J. 2020 Oct 21;41(40):3925-3932. doi: 10.1093/eurheartj/ehaa652. Eur Heart J. 2020. PMID: 32860032 Free PMC article. Clinical Trial.
Underlying mechanisms involved in the icosapent ethyl reduction of cardiovascular events still cannot be attributed to an anti-atherosclerotic effect.
Rodriguez-Granillo GA, Garcia-Garcia HM. Rodriguez-Granillo GA, et al. Eur Heart J. 2021 Aug 17;42(31):3023-3024. doi: 10.1093/eurheartj/ehab230. Eur Heart J. 2021. PMID: 33970235 No abstract available.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information